ALMEDIS is a contract research and consultancy organization, providing comprehensive support to pharmaceutical and biotech companies, academic institutions and contract research organizations.
ALMEDIS provides the full package of services for allocation, management, and execution of clinical trials: medical writing, feasibility assessment, regulatory approval, site monitoring, site management, project management, medical monitoring, data management, statistical analysis, clinical study report.
ALMEDIS services include regulatory affairs, consultancy in the field of medical marketing and quality assurance in clinical studies. ALMEDIS was founded in 2006, Head Office is located in Moscow.
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics.
A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient.
have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses.
With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.
To learn more about our pioneering science and vital medicines, visit www.amgen.com
AstraZeneca is a global innovation-driven biopharmaceutical company focused on delivering great medicines to patients through innovative science and excellence in development and commercialisation.
AstraZeneca’s expertise spans the entire life-cycle of a medicine and the company has capabilities in both small molecules and biologics.
Science and patients are at the heart of everything AstraZeneca does. The company conducts its research across 3 continents and invests over $4 billion each year in the discovery and development of the next generation of innovative medicines targeting unmet needs.
AstraZeneca primarily focuses on cancer, cardiovascular/metabolic disease and respiratory, inflammatory and autoimmune disease. Alongside this, the company is active in infection and neuroscience with targeted investments in opportunities and collaborations.
AstraZeneca employs around 50,000 people worldwide in over 100 countries. Company’s sales in 2013 totaled over $25,7 billion.
Russia is one of the key markets for AstraZeneca. AstraZeneca has been present in Russia since 1993 and now employs more than 1,400 people across around 80 cities. Around 40 of AstraZeneca’s innovative medicines are licensed for sale in Russia. One of the key goals of AstraZeneca Russia is to make a contribution to shaping innovative pharmaceutical industry in Russia. In 2011 AstraZeneca began construction of a new $187 million manufacturing facility in the Kaluga region and launched several projects to support R&D progress in Russia.
– is one of the ten largest specialty pharmaceutical companies in the world. The company markets its products in more than 100 countries, and in 2008 generated sales of over ˆ10.7 billion. Approx. 38,000 members of staff currently work for Bayer Schering Pharma worldwide – more than 5,600 in research and development alone.
The 2006 acquisition of Schering was the largest purchase in Bayer’s history. The resulting entity Bayer Schering Pharma, a division of Bayer HealthCare, markedly increases the company’s expertise in the field of pharmaceutical specialties. Combining the expertise of two companies rich in tradition, Bayer Schering Pharma is a leading player both in Germany and in the international arena.
Berlin and Wuppertal in Germany, Berkeley in the United States are the lead research centers in the world.
Manufacturing centers of the company are located in Europe, the United States, Latin America and Asia.
The research and business activities of Bayer Schering Pharma AG are concentrated on four strategic units: Diagnostic Imaging, General Medicine, Specialty Medicine and Women’s Healthcare.
Bayer Schering Pharma aims to improve people’s quality of life with its products. To achieve this, the company concentrates on the research and development of innovative drugs and novel therapeutic approaches. At the same time, Bayer Schering Pharma is constantly improving established products. In this context, Bayer Schering Pharma uses experience it has gained from over a century in the business.
The research and business activities of Bayer Schering Pharma AG are concentrated on four strategic units in which the company makes essential contributions to medical progress:
1. Diagnostic Imaging. Contrast media for the precise and early detectionof clinical pictures in CT and MR examinations. 2. General Medicine. Products for high blood pressure, venous thromboembolism, coronary heart diseases, diabetes and infectious diseases, as well as erectile dysfunction and testosterone deficiency in men. 3. Specialty Medicine. Treatment options for multiple sclerosis, hemophiliaand certain types of cancer. 4. Women’s Healthcare. Hormonal contraception, menopause management and gynecological therapies.
Business operations in Russia have seen strong growth rates over the past years with the Russian pharmaceutical market being one of the fastest-growing major markets in the world. The potential for industry growth in the Russian pharmaceuticals sector remains considerable, owing to the size of the population and its current low drug-consumption rate.
Along with the growth of business and – since January 2007 – the responsibility for both, former Schering’s and Bayer’s pharmaceutical product portfolio, the number of employees has been risen to more than 500. The product portfolio sold is nearly identical to the Western European one.
Development of Clinical Research – one of the important ways of development of the company in Russia.
is a group of companies dedicated to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. It is one of the world’s 20 leading pharmaceutical companies.
142 affiliated companies in 47 countries
Our corporate vision - "Value through Innovation"
The objectives and beliefs of Boehringer Ingelheim can be summed up in a single phrase: Value through Innovation. This vision has helped us to build on our strengths and make the most of our distinctive character. In a competitive and fast-changing world, the value of products, services and companies is constantly changing. Real customer value today can only be created by constantly developing new solutions and doing what we already do better.
Boehringer Ingelheim was founded in Ingelheim am Rhein (Germany) in 1885, where the corporate headquarters is still located.
Consumer Health Care
Research & Development
We are spending 21% of net sales in our largest business segment Prescription Medicines (2009) on R&D. We have four main R&D sites and three smaller specialised sites worldwide, which focus on six major therapeutic areas:
Uncovering Answers to Protect Patients´ Health
Boehringer Ingelheim has a large and experienced global team managing and conducting clinical trials in many indications. During the past decade from 200 to 2009, Boehringer Ingelheim conducted or sponsored 1,296 studies with 112 substances in 84 countries from all regions of the world.
Zemlyanoi Val, bld. 9
Business Center "CitiDel"
phone: + 7 495 755 9267
fax: + 7 495 755 9273
Bristol-Myers Squibb Company – American pharmaceutical company. It was founded in 1989 by merging of Bristol-Myers (founded in 1887) with Squibb (founded in 1858). Headquarters are located in New York. Company has more than 42 thousand employees around the world.
Company develops, researches, produces and sales pharmaceutical drugs. The main therapeutical areas are: oncology, cardiology, infectious and viral diseases, psychiatry and etc.
CHILTERN INTERNATIONAL LLC,
64, Building 1, Lit. A, Serdobolskaya Street,
Bely Ostrov (White Island),
St. Petersburg, 197342,
Tel.:+7 (812) 325 11 18 www.chiltern.com
Chiltern, a global contract research organization, is a leading provider of clinical solutions in a variety of specialty areas and engagement models for biopharmaceutical and medical device industries. Chiltern’s team of more than 4,200, located across 47 countries, provides comprehensive Clinical Development, Medical & Scientific Affairs, Data & Analysis, Pharmacovigilance, Strategic Regulatory and Clinical Supplies services using a collaborative approach to maximize efficiency and minimize delays. Visit www.chiltern.com to learn more about how Chiltern is Designed Around You®
Covance, with headquarters in Princeton, New Jersey, is one of the world’s largest and most comprehensive drug development services companies, with annual revenues greater than $1.8 billion and 10,000 employees in more than 25 countries. Covance has the people, processes, client service, and global resource capabilities to respond to biotechnology and pharmaceutical clients’ toughest drug development challenges.
With the most comprehensive portfolio of discovery, preclinical, clinical development and commercialization services, Covance provides industry-leading services, the world’s largest central laboratory network, and a global team of clinical trial and commercialization experts.
Dokumeds is a clinical development company that provides full-service, state-of-the-art expertise and functionality to the drug, biologics and medical device industries. We excel in managing studies for our client’s products which is demonstrated by our successes with a number of the largest 30 biopharmaceutical companies.
Founded in 1995, Dokumeds is privately-held, and managed by medical doctors with backgrounds in academia and industry prior to founding the company. Dokumeds is able to support sponsors through the entire clinical development lifecycle from study design through the final submission of package, and in all clinical Phases.
Dokumeds has seven offices, and is currently active in 19 countries in Europe. All of our staff are based in-country, and are fluent in both their native languages and English. In Russia, Dokumeds is able to control the entire logistical supply-chain through its own state-of-the-art drug warehouse and distribution unit located in Moscow.
Our project teams consist of exceptionally talented personnel. That, in conjunction with our extensive clinical trials experience, local know-how and the backgrounds of our management team combine to make Dokumeds a unique and logical partner in Central and Eastern Europe.
Eli Lilly is one of the largest pharmaceutical research-based companies in the world. Company was founded in May 1876 in Indianapolis, Indiana. Lilly has long-term experience in introduction of the innovative decisions directed on effective treatment of variety of diseases, first of all in the field of oncology, endocrinology, infectious diseases, psychiatry, neurology, cardiology and urology.
Lilly's global employees number more than 40,000. The medicines of the company are marketed in 143 countries. Lilly has major research and development facilities in nine countries and conducts clinical trials in more than 30 countries.
Russian affiliate of Eli Lilly has been established more than 18 years ago. Currently, Clinical Research Department of Lilly Russia is conducting more than 30 both large international and local trials in above-mentioned therapeutic areas.
More than 70 leading research and clinical centers are Lilly partners in the field of clinical research. All clinical trials sponsored by Lilly are conducted in accordance with high international ethical standards and current legislation of Russian Federation.
ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries.
We specialise in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I-IV clinical studies.
We are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis.
We have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated "full service" solution.
INC Research (Nasdaq: INCR) is a leading global contract research organization (CRO) providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industry. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. We were ranked "Top CRO to Work With" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 100 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter inc_research.
inVentiv Health Clinical, formerly PharmaNet/i3, is a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and strategic resourcing from a single clinical professional to an entire functional team.
With 7,000 passionate employees in more than 36 countries, inVentiv Health Clinical works to accelerate high quality drug development programs of all sizes around the world. inVentiv Health Clinical is part of inVentiv Health, a best-in-class team of global healthcare experts offering clinical, commercial and consulting services designed to provide a comprehensive customer experience that delivers greater long term value.
17/2 Krylatskaya str.
121614 Moscow, Russia
Tel.: + 7 (495) 755 83 57
Fax: +7 (495) 755 83 58
Janssen Pharmaceutica N.V.(Belgium) – pharmaceutical company focusing on research and development of new medicines. The company was founded in 1953 by prominent Belgian pharmacologist Paul Janssen and belongs to worldwide renowned international corporation Johnson & Johnson.
Company representative offices are located in more than 40 countries with more than 22,000 employees worldwide.
Janssen Pharmaceutica N.V. is one of the leaders in worldwide pharmaceutical industry. The company developed more than 80 original medicines including Galoperidol, Phentanil, Rispolept, Orungal, Nizoral, Motilium and others.
Main scientific research areas of the company are represented by psychiatry, neurology, oncology, gastroenterology and dermatology.
Antipsychotic drug Rispolept developed by Janssen Pharmaceutica N.V. was honored with international Galen award, which is the highest international award and recognition of outstanding achievement in pharmaceutical industry.
Five medicines developed by Janssen Pharmaceutica N.V. are included in World Health Organization list of vitally important medicines. This is more than any other pharmaceutical company has ever achieved.
Main goal of Janssen Pharmaceutica N.V. is development of new and effective medicines to help patients and improve quality of life. Excellent worldwide reputation of Janssen Pharmaceutica N.V. in medical professional world is constantly maintained by the company’s strict adherence to high quality standards and innovations.
16 Letnikovskaya Str.,
Business Center “Siberian Alliance”,
Tel: +7 495 730 58 30
Fax: +7 495 730 58 31
Am Kupfergraben 4-4a
Tel: +49 30 20607975
KCR is a Contract Research Organization (CRO) providing strategic clinical development solutions for the pharmaceutical, biotechnology and medical device industries.
Active in the industry since 1997 KCR has gathered comprehensive expertise in the execution of clinical trials with over 450 studies conducted, more than 4000 investigational sites contracted, and above 45000 patients recruited. Focusing on knowledge, quality and innovation, KCR offers high value solutions customized to clients' needs.
More than 300 KCR professionals offer full service capabilities across the three main service areas:
Trial Execution (TE)
Functional Service Provision (FS)
Late Phase (LP)
The company’s geographical set up suits perfectly to deliver optimized trial execution strategies. Headquartered in Berlin, Germany, KCR operates across 19 countries in Europe as well as the U.S.
For more information, visit www.kcrcro.com or contact us at
is a full-service CRO for international sponsors conducting phase I to phase IV studies in Russia, Ukraine, Georgia, Belarus, and Kazakhstan. Since 1997 MB Quest has improved the health of people by maintaining high ethical standards and a culture that values honesty and integrity in all aspects of research. MB Quest has offices in Moscow, St. Petersburg, Novosibirsk, Kiev, Tbilisi, Minsk, and local staff in Kazakhstan.
is a Clinical Research Organization (CRO) that provides clinical development services for the pharmaceutical and biotechnology industries.
Clinical trial experience in over 40 countries
Corporate headquarters in Cincinnati, Ohio; European Headquarters in the Netherlands
Key offices in 14 countries, including Belgium, Brazil, China, Czech Republic, Germany, India, Israel, and Switzerland.
A global leader in research-based drug development, Medpace builds strong strategic partnerships with select Sponsors to advance the most efficient and cost-effective path to drug approval. As a therapeutically-focused Clinical Research Organization (CRO), we view ourselves as stewards of Sponsors drug, leveraging our extensive medical and regulatory expertise to deliver additional input, strategy, and efficiencies to each and every phase of the clinical trial. From custom solutions addressing the needs of small and midsize biotechnology companies to full-service offerings for global pharmaceutical companies, Medpace has the breadth, depth, and flexibility to deliver a superior result, specific to your needs.
Medpace has the global reach and capability to conduct studies, assist sponsors with regulatory requirements, and deliver custom solutions through regional offices located throughout Europe, Asia, Australia, South Africa, and the Americas, with staff and offices continually added throughout the world. Integration of Clinical Pharmacology, Central Laboratory, Imaging, and Bioanalytical capabilities into the design of a clinical trial allows Sponsors the most efficient global trial conduct from discovery to post marketing.
Medpace personnel have a deeper understanding of local language, culture, and processes, which creates better relationships with investigators and improved trial execution. They have greater access to the country patient populations for faster enrollment timelines and lower costs.
Medpace offers an innovative suite of proprietary, leading edge technologies, ClinTrak®, a study management system facilitating team coordination and providing decision support for sponsors and sites to ensure global teams are focused and organized for maximum efficiencies using a common data platform. ClinTrak provides near real time access to critical study data, tracking, interpreting, and communicating information in the most timely, secure, and cost-effective manner.
We know what's most important to investigators – good protocol design, project planning and organization, and open, effective communication.
is recognized as one of the world leaders in pharmaceutical industry.
The Novartis Group of companies offers a wide range of pharmaceuticals to meet the needs of modern healthcare system, including innovative prescription medications (Novartis Pharma), top-quality generics (Sandoz), over-the-counter medicine (Novartis Consumer Health), as well as vaccines and test systems (Novartis Vaccines and Diagnostics).
Novarties Group employs over 100,000 staff and operates in 140 countries worldwide, Russia included, to best meet the needs of the patients.
Novartis production facilities are based in Basel (Switzerland), Grimsby (U.K.), Huningue (France), Kundl and Schaftenau (Austria), Kurtköy (Turkey), Lincoln (NE, United States), Ringaskiddy (Ireland), Singapore, Stein and Schweizerhalle (Switzerland), Suffern (NY, United States).
Novartis major research centers:
Novartis Institutes for Biomedical Research (NIBR), Emeryville, East Hanover, Cambridge (MA), Horsham, Basel, Shanghai
Novartis Institute for Tropical Diseases (NITD), Singapore
Novartis Vaccines Institute for Global Health (NVGH), Siena (Italy)
Genomics Institute of the Novartis Research Foundation (GNF), La Jolla (CA)
Friedrich Miescher Institute for Biomedical Research (FMI), Basel (Switzerland)
The Group sales in 2009 reached USD 44.3 billion. Novartis has been named the Super Sector Leader among healthcare companies in the 2008 and 2009 updates of the Dow Jones Sustainability Index.
Novartis is rightfully considered to be one of the most rapidly growing companies in healthcare sector and having an extensive portfolio of drugs with valid patents and molecule formulation. Cardiology, metabolism, endocrinology, oncology, neurology, ophthalmology, transplantology, respiratory and infectious diseases comprise the strategic focus of Novartis.
With USD 7.5 billion invested in R&D activities, the Novartis program covers 145 projects aiming both to develop new medications and to improve the existing ones.
Innovation is the underlying principle of the Novartis developments. Novartis was ranked No. 1 by the Fast Company on the biotechnology sector list in 2010. Innovation based on the top-notch level research, ongoing optimization of strategies and processes give serious hope for meeting the most pressing medical needs and improving the quality of life of patients worldwide.
Novo Nordisk LLC
Russia, 119330, Moscow,
Lomonosovsky pr. 38, office 11
Tel: (+7 495) 956-11-32
Fax: (+7 495) 956-50-13
Diabetes Hot Line: 8-800-3333-706
(toll-free in Russia)
Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. Novo Nordisk offers one of the broadest portfolios of diabetes products in the industry, including advanced insulin delivery systems. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 30,900 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
In Russia, Novo Nordisk products are known for more than 60 years, during which its standards of quality and efficiency have been recognized by local healthcare professionals and patients. Novo Nordisk representative office was opened in Russia in 1991, and today it employs more than 200 employees working in all regions of the country. The priority for Novo Nordisk in Russia is to increase the accessibility of innovative diabetes treatment for Russian patients. For this purpose the company is investing into the modern insulin plant in the Kaluga region.
In order to contribute to the development of the healthcare system in Russia, and strengthen the nation’s health, Novo Nordisk is also conducting broad outreach, educational and humanitarian campaigns.
PAREXEL is a proven and committed partner to drug developers and medical device manufacturers looking to bring innovative new products to market. Our Phase I-IV studies incorporate the full range of services from clinical study design to bioanalytics to peri-approval and post-marketing services, with an emphasis on First in Man and Proof of Concept studies. We have decades of experience, deep expertise, and the global resources required to handle studies – and programs of studies – of any size, anywhere in the world.
PAREXEL has extensive experience in more than two dozen key therapeutic areas, with particular expertise in Cardiovascular, CNS, Infectious Disease, and Oncology.
Over the past 25 years, PAREXEL has developed significant expertise to assist clients in the worldwide pharmaceutical, biotechnology and medical device industries with the development and launch of their products in order to bring safe and effective treatments to the global marketplace for the patients who need them. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has more than 7,300 employees.
In Russia PAREXEL is represented by PAREXEL International (RUS) LLC (PAREXEL Russia AS representative office in 1998-2006). Services are provided in clinical trials phase I-IV, drug development consulting, data management, biostatistics and programming, quality assurance, proposal and contracts. PAREXEL international (RUS) LLC has over 170 employees and offices located in Moscow and St. Petersburg.
Pfizer is the leading pharmaceutical company in the world dedicated to developing new, safe medicines to prevent and treat the world's most serious diseases.
Pfizer was founded in 1849 in New York and now works in more than 150 countries. Pfizer R&D centers are in Great Britain and the USA. Pfizer has been working in Russia since 1992.
Pfizer has the largest pipeline in the pharmaceutical industry and annually invests more than $7 billion in research and new drugs development.
ul. Smolnaya 24/D
Moscow, 125445, Russia
òåëåôîí: +7 (495) 234-57-51
ôàêñ: +7 (495) 956-61-76
PRA Health Sciences delivers innovative drug development solutions that improve patients’ lives. Our people work tirelessly to provide quality results for clients. We offer specialized expertise across all phases, therapeutic areas and a broad spectrum of full-service and strategic solutions.
With 10,000+ employees covering 80+ countries, we give you the global presence you expect, combined with an in-depth knowledge of local regulations, standards of care and cultural customs.
At PRA, we love what do, because we are making a difference in the lives of patients and their family members worldwide. We have contributed to the development of numerous drugs now available to countless patients.
Shevchenko Street, 65B
Tel. (+7 4812) 207 500
Fax (+7 4812) 207 600
PPD, is a leading global contract research organization, celebrating 25 years of providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 42 countries and more than 11,000 professionals worldwide, PPDs Russian offices are located in Smolensk, Moscow, St. Petersburg and Novosibirsk, employing more than 210 employees. PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.
BioDuro, A PPD® Company
A drug discovery services company focused on integrated drug discovery programs
Clinical Development Services:
Phase I clinic
Phase II-IIIb trial management and monitoring
Biostatistics and programming
Data management, including EDC
Device development services
Global central labs
Interactive voice response systems
Regulatory management and dossier submissions
Site and patient recruitment
Vaccines and biologics lab
Late stage research
Epidemiology: pharmacoepidemiology and health outcomes
Phase IIIb-IV trials
Risk management, REMS
Safety surveillance studies
19/21 Dostoyevsky Street
191119 St. Petersburg
Tel: +7 812 320 3820
Fax: +7 812 320 3850
203 Redwood Shores Parkway,
Redwood City, CA 94065
Tel: +1 650 592 9101
Fax: +1 650 592 9109
PSI is a leading full-service CRO with 700+ full-time staff across Europe and North America.
PSI has always been distinguished by exceptionally strong presence in Central and Eastern Europe - the region that has over the years become a major provider of clinical trial data for international drug development sponsors.
The largest office and the operational headquarters are in St. Petersburg, Russia (450 people). From St. Petersburg - beginning in 1995 - the Company has grown organically to offices in Russia, Ukraine, Romania, Bulgaria, Poland, Estonia, Czech Republic, Switzerland and the USA. In the US, PSI has an operational office in Philadelphia and a business development office in San Francisco. The mother company, PSI CRO AG, is in Zug, Switzerland. In Western Europe, PSI’s operational presence stretches out to Germany, Austria, France, Hungary and the Baltic countries. PSI is privately owned. For more information go to www.psi-cro.com
Leningradskiy prospekt 37A, bldg.14
125167 Moscow, Russia
tel: (+7 495) 721 19 64
fax: (+7 495) 725 10 38
QuintilesIMS is a global leader in pharmaceutical services, improving healthcare worldwide by providing innovative, quality professional expertise, market intelligence and partnering solutions to meet the dynamic needs of pharmaceutical, biotechnology and healthcare industries. Founded in 1982 by Dennis Gillings, Ph.D., CBE, and headquartered near Research Triangle Park, North Carolina, now QuintilesIMS has more than 20000 employees conducting clinical trials in more than 90 countries all over the world.
QuintilesIMS is one of founders of organization and development of clinical trials in Russia. Since 1996 QuintilesIMS has made an important contribution to expanding of geography of international clinical trials’ participants and also to increasing of their quality. The highly qualified employees work in offices situated in Moscow, Saint Petersburg and Novosibirsk.
The main course of company’s activity in Russia is conducting of clinical trials in the area of cardiology, oncology, psychiatry and others in research sites (academic scientific centers, medical scientific research institutes, clinics, hospitals) in the cities: Moscow, Saint Petersburg, Voronezh, Yaroslavl, Kaluga, Samara, Kazan, Volgograd, Obninsk, Tomsk, Tyumen, Krasnoyarsk, Arkhangelsk, Yekaterinburg, Novosibirsk, Chita and other cities.
Les Laboratoires Servier
2, Paveletskaya square, Bld. 3
115054, Moscow, Russia
The French Pharmaceutical Group SERVIER was founded in 1954 by Doctor Jacques Servier. Doctor Jacques Servier is the President of the Group.
The French Pharmaceutical Group SERVIER is today one of the most actively developing and quickly growing pharmaceutical companies in the world as well as in Russia. During 30 years the company registered more than 30 original medicines.
SERVIER’s worldwide workforce is over 20 000 including nearly 3 000 in Research and Development.
Every year more than 25% of SERVIER’s turnover is invested in Research and Development.
SERVIER’s medicines are now presented in 140 countries of the world.
SERVIER was established in Russia in 1992. Due to permanent investments and strict observance of the strategy based on ethics and scientific investigations SERVIER became one of the leaders of the pharmaceutical market. Medicines for treatment of cardiovascular system, diabetes, central nervous system, respiratory diseases, oncology diseases and other are presented in Russia.
SERVIER is well known by its cooperation with Russian scientific societies and associations in the field of organization of educational programs, ìedical congresses, scientific studies which are directed to the development of Russian health care system, scientific knowledge diffusion among medical doctors and development of medical information awareness of patients, specifically, in cardiovascular diseases, respiratory diseases, diabetes and other.
Worldwide Clinical Trials (WCT) is a leading provider of international contract clinical research services, focusing on early and late-stage drug development services for pharmaceutical and biotechnology companies. We develop sophisticated and innovative approaches to research, with primary focus in the areas of cardiovascular and central nervous system medicine, along with significant experience in Chronic Inflammatory Disease, Metabolic / Endocrinology and Oncology. In 2008 the Evidence Company became the integral part of the WCT organization.
401 North Maple Drive
Beverly Hills, CA 90210 Tel: (310) 786-9100
Fax: (310) 786-9101
Central / Eastern Europe & Russia
14, 13th Line V.O.,
St. Petersburg, 199034
Tel: 7 (812) 346 8247
Fax: 7 (812) 346 8248